002728.SZ
特一药业
SZSE · Healthcare · C 制造业 · CN
CNY 8.60
−3.37%Year over year
Reported trailing growth
- Revenue
- +2.6%
- EBITDA
- —
- EBIT
- +46.0%
- EPS
- +83.5%
- Free cash flow
- +3349.5%
- Operating cash flow
- +56.7%
Forward estimates
Based on analyst estimates
- Revenue
- -54.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.4%
- EBITDA
- -15.4%
- EBIT
- -25.5%
- Net income
- -22.9%
- EPS
- -34.5%
- Free cash flow
- -16.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026